News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 31, 2025

Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

Author(s)Hadar Lev-Tov, MD

Panelist discusses how patient advocacy groups act as critical bridges between patients, researchers, and health care providers, ultimately improving recognition, treatment, and quality of life for individuals affected by hidradenitis suppurativa.

Episodes in this series

1 expert is featured in this series.

EP. 1 Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

1 expert is featured in this series.

EP. 2 Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

1 expert is featured in this series.

EP. 3 Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

1 expert is featured in this series.

EP. 4 Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

1 expert is featured in this series.

EP. 5 Strategies for Equitable Access in Hidradenitis Suppurativa

1 expert is featured in this series.

EP. 6 Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

1 expert is featured in this series.

EP. 7 Holistic Care for HS Patients: The Power of Multidisciplinary Models

1 expert is featured in this series.

EP. 8 The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

1 expert is featured in this series.

EP. 9 Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management

1 expert is featured in this series.

EP. 10 The Value Proposition: Justifying the Investment in HS Centers of Excellence

1 expert is featured in this series.

EP. 11 Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

1 expert is featured in this series.

EP. 12 Navigating HS Management: The Patient Journey

1 expert is featured in this series.

EP. 13 Advancing HS Outcomes: Resource Prioritization and Success Measurement

1 expert is featured in this series.

EP. 14 Tailoring HS Treatment: The Path to Better Patient Outcomes

Video content above is prompted by the following:

Can you discuss the role of patient advocacy groups in promoting early recognition and comprehensive care for HS?
Closing thoughts on HS for the AJMC viewing audience.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Zobair M. Younossi, MD

Lifestyle Factors Offer Actionable Targets in MASLD Management: Zobair M. Younossi, MD

ByBrooke McCormick,Zobair M. Younossi, MD,Laura Joszt, MA

August 16th 2026

soft tissue sarcoma image | Image credit: Dr_Microbe - stock.adobe.com

Sarcoma Gene Signature May Predict Who Benefits From Pazopanib

ByLaura Joszt, MA

August 16th 2026

Matthew A. Lunning, DO, FACP, discussed the prospects for use of bispecifics following R-CHOP in DLBCL in a recent interview. | Image: University of Nebraska College of Medicine

Lunning Sees Use of Bispecifics in Consolidation Phase in DBLCL

August 14th 2026

Retatrutide injection pen — Eli Lilly's investigational triple agonist GLP-1 drug | Image credit: Anna Hoychuk - stock.adobe.com

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

ByPearl Steinzor

August 14th 2026

Lidia Schapira, MD

Adapting Breast Cancer Therapy to the Individual, Not Just the Scan: Lidia Schapira, MD

ByGiuliana Grossi,Lidia Schapira, MD, FASCO

August 14th 2026

Trending on AJMC

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

Sarcoma Gene Signature May Predict Who Benefits From Pazopanib

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis

Lifestyle Factors Offer Actionable Targets in MASLD Management: Zobair M. Younossi, MD

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care